# Table of Contents

## Breaking Advances

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

## Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4565</td>
<td>ACVR1 Mutations in DIPG: Lessons Learned from FOP</td>
<td>Kathryn R. Taylor, Maria Vinci, Alex N. Bullock, and Chris Jones</td>
</tr>
</tbody>
</table>

## Physics in Cancer Research

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4572</td>
<td>Introduction to Physics in Cancer Research</td>
<td>Herbert Levine</td>
</tr>
<tr>
<td>4574</td>
<td>Toward Decoding the Principles of Cancer Metastasis Circuits</td>
<td>Mingyang Lu, Mohit Kumar Jolly, Jose’ Onuchic, and Eshel Ben-Jacob</td>
</tr>
<tr>
<td>4588</td>
<td>Modeling Contact Guidance and Invasion by Cancer Cells</td>
<td>Leonard M. Sander</td>
</tr>
<tr>
<td>4597</td>
<td>Force Engages Vinculin and Promotes Tumor Progression by Enhancing PI3K Activation of Phosphatidylinositol (3,4,5)-Triphosphate</td>
<td>Matthew G. Rubashkin, Luke Cassereau, Russell Bainer, Christopher C. DuFort, Yoshihiro Yui, Guanqing Ou, Matthew J. Paszek, Michael W. Davidson, Yunn-Yi Chen, and Valerie M. Weaver</td>
</tr>
<tr>
<td>4612</td>
<td>Using High-Throughput Transcriptomic Data for Prognosis: A Critical Overview and Perspectives</td>
<td>Eytan Domany</td>
</tr>
<tr>
<td>4622</td>
<td>Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma</td>
<td>Jayashree Kalpathy-Cramer, Elizabeth R. Gerstner, Kyrr E. Emblem, Ovidiu C. Andronesi, and Bruce Rosen</td>
</tr>
</tbody>
</table>

## Meeting Report

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4671</td>
<td>Mouse Models of Human Cancer</td>
<td>Barbara C. Böck, Ulrike Stein, Clemens A. Schmitt, and Hellmut G. Augustin</td>
</tr>
</tbody>
</table>

## Priority Report

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4676</td>
<td>Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC</td>
<td>Jeremy H. Tchaicha, Esra A. Akbay, Abigail Altabef, Oliver R. Mikse, Eiki Kikuchi, Kevin Rhee, Rachel G. Liao, Roderick T. Bronson, Lynette M. Sholl, Matthew Meyerson, Peter S. Hammerman, and Kwok-Kin Wong</td>
</tr>
</tbody>
</table>

*Précis:* In developing a unique mouse model of lung adenocarcinoma, this study may improve what have been limited opportunities for preclinical drug discovery and development in this setting.
INTEGRATED SYSTEMS AND TECHNOLOGIES

4685 Polarization-Sensitive Multimodal Imaging for Detecting Breast Cancer
Rakesh Patel, Ashraf Khan, Robert Quinlan, and Anna N. Yaroslavsky
Précis: This study describes a novel noninvasive imaging method that allows for rapid and accurate intraoperative detection of breast cancer margins.

4694 A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets
Ayumu Taguchi, Allen D. Taylor, Jaime Rodriguez, Muğe Celiktaş, Hui Liu, Xiaotu Ma, Qing Zhang, Chee-Hong Wong, Alice Chin, Luc Girard, Carmen Behrens, Wan L. Lam, Stephen Lam, John D. Minna, Ignacio I. Wistuba, Adi F. Gazdar, and Samir M. Hanash
Précis: These results offer preclinical proof-of-concept for an Hsp70 regulatory complex as an appealing anticancer target for the generalized treatment of human malignancy.

Molecular and Cellular Pathobiology

4731 Hsp70–Bag3 Interactions Regulate Cancer-Related Signaling Networks
Précis: These results offer preclinical proof-of-concept for an Hsp70 regulatory complex as an appealing anticancer target for the generalized treatment of human malignancy.

4741 NACK Is an Integral Component of the Notch Transcriptional Activation Complex and Is Critical for Development and Tumorigenesis
Kelly L. Weaver, Marie-Clo tidile Alves-Guerra, Ke Jin, Zhiqiang Wang, Xiaqing Han, Prathibba Ranganathavan, Xiaoxia Zhu, Thiago DaSilva, Wei Liu, Francesca Ratti, Renee M. Demarest, Cristos Tzimas, Meghan Rice, Rodrigo Vasquez-Del Carpio, Nadia Dahmane, David J. Robbins, and Anthony J. Capobianco
Précis: This study illuminates a novel critical part of the Notch receptor signaling pathway, which has emerged as an important driver of a variety of aggressive human cancers.

Microenvironment and Immunology

4706 Osteopontin Shapes Immunosuppression in the Metastatic Niche
Sabina Sangaleiti, Claudio Tripodo, Sara Sandri, Ilaria Torselli, Caterina Vitali, Chiara Ratti, Laura Botti, Alessia Burocchi, Rossana Porcasi, Andrea Tomirotti, Mario P. Colombo, and Claudia Chiiodoni
Précis: Activities of a prometastatic molecule appear to differ to some extent when produced by tumor cells versus host immune cells however, from either source it helps establish local immunosuppression within metastatic sites.

4720 IL-1β-Mediated Repression of microRNA-101 Is Crucial for Inflammation-Promoted Lung Tumorigenesis
Lin Wang, Ling-Fei Zhang, Jing Wu, Shu-Jun Xu, Yang-Yang Xu, Dangsheng Li, Jia-Tao Lou, and Mo-Fang Liu
Précis: microRNA-101 provides a molecular connection between pathogenic inflammation and lung tumorigenesis by regulating Lin28B, an oncogenic RNA-binding protein with pleiotropic roles in cancer including stem-like cell function.

Therapeutics, Targets, and Chemical Biology

4752 Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2
Yun-Han Lee, Daekwan Seo, Kyung-Ju Choi, Jesper B. Andersen, Min-Ah Won, Mitsu teru Kitade, Luis E. Gómez-Quiroz, Adam D. Judge, Jens U. Marquardt, Chiara Raggi, Elizabeth A. Conner, Ian MacLachlan, Valentina M. Factor, and Snorri S. Thorgeirsson
Précis: Systemic inactivation of a disease-specific HDAC isoform can achieve therapeutic efficacy, as shown by this preclinical proof-of-concept study for treatment of liver cancer.

4762 Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression
Jennifer L. Yori, Kristen L. Lozada, Darcie D. Seachrist, Jonathan D. Mosley, Fadi W. Abdul-Karim, Christine N. Booth, Chris A. Flask, and Ruth A. Keri
Précis: Results from this combination therapy study may help improve the mainly inefficacious effects of mTOR inhibitors in clinical trials, addressing the weaknesses of an erstwhile general approach to cancer cell eradication.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4772</td>
<td>Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop</td>
<td>Aleksandra Pandya, Peter J. Mullen, Manpreet Kalkat, Rosemary Yu, Janice T. Pong, Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, and Linda Z. Penn</td>
</tr>
<tr>
<td>4783</td>
<td>AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt–MDM2–Foxo3a Signaling Axis</td>
<td>Chih-Chien Chou, Kuen-Haur Lee, I-Lu Lai, Dasheng Wang, Xiaokui Mo, Samuel K. Kulp, Charles L. Shapiro, and Ching-Shih Chen</td>
</tr>
<tr>
<td>4796</td>
<td>Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4</td>
<td>Christina A. von Roemeling, Derek C. Radisky, Laura A. Marlow, Simon J. Cooper, Stefan K. Grebe, Panagiotis Z. Anastasiadis, Han W. Tun, and John A. Copland</td>
</tr>
<tr>
<td>4811</td>
<td>Pyrvinium Attenuates Hedgehog Signaling Downstream of Smoothened</td>
<td>Bin Li, Dennis Liang Pei, Colin A. Flaveny, Nadia Dahmane, Valerie Baubet, Zhiqiang Wang, Feng Bai, Xin-Hai Pei, Jezabel Rodrigez-Blanco, Brian Hang, Darren Orton, Lu Han, Baolin Wang, Anthony J. Capobianco, Ethan Lee, and David J. Robbins</td>
</tr>
</tbody>
</table>

**Table of Contents**

4822 Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer

Yi-Hsin Hsu, Jun Yao, Li-Chuan Chan, Ting-Jung Wu, Jennifer L. Hsu, Yueh-Fu Fang, Yongkun Wei, Yun Wu, Wen-Chien Huang, Chien-Liang Liu, Yuan-Ching Chang, Ming-Yang Wang, Chia-Wei Li, Jia Shen, Mei-Kuang Chen, Aysegul A. Sahin, Anil Sood, Gordon B. Mills, Dihua Yu, Gabriel N. Hortobagyi, and Mien-Chie Hung

**Précis:** These findings define three kinases critical for growth of an aggressive subtype of breast cancer, offering a preclinical rationale to target their activity as an effective therapy.

4836 Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance

Shigeo Ohba, Joydeep Mukherjee, Wendy L. See, and Russell O. Pieper

**Précis:** Mutation of a key metabolic contributor to glioma development indirectly enhances homologous recombination-based repair of DNA damage triggered by the chemotherapy drug temozolomide, offering an explanation for the intrinsic resistance of gliomas to this drug and a rational path forward toward their eradication.

4845 The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF

Ian R. Watson, Liren Li, Peter K. Cabeciras, Mozhe deh Mahdavi, Tony Gutscner, Giannicola Genovese, Guocan Wang, Zhuangna Fang, James M. Tepper, Katherine Stemke-Hale, Kenneth Y. Tsai, Michael A. Davies, Gordon B. Mills, and Lynda Chin

**Précis:** This timely report suggests a novel predictive biomarker for the efficacious response of melanoma patients to BRAF inhibitors, the most effective use of which has yet to be fully elucidated.

4853 Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER- Breast Cancer

David Endesfelder, Rebecca A. Burrell, Nnennaya Kanu, Nicholas McGranahan, Mike Howell, Peter J. Parker, Julian Downward, Charles Swanton, and Maik Kschisch

**Précis:** Chromosomal instability, a hallmark of cancer cells, permits a selection for gene copy number alternations in core regulators of proliferation that have prognostic value.
Epigenetic States of Cells of Origin and Tumor Evolution Drive Tumor-Initiating Cell Phenotype and Tumor Heterogeneity

Kin-Hoe Chow, Dong-Mi Shin, Molly H. Jenkins, Emily E. Miller, David J. Shih, Seungbum Choi, Benjamin E. Low, Vivek Philip, Brad Rybinski, Roderick T. Bronson, Michael D. Taylor, and Kyuson Yun

Précis: This study probes the sources of tumor heterogeneity, a core research challenge that—despite its recognition by clinical pathologists for many years and its recent rediscovery by molecular geneticists—still represents the chief weakness of all cancer cell-targeted therapeutic strategies.

TRIM29 Suppresses TWIST1 and Invasive Breast Cancer Behavior


Précis: TRIM29 exerts complex roles in cancer, but in breast cancer it appears to function as a tumor suppressor by suppressing a core regulator of the epithelial–mesenchymal transition, a pivotal step in driving invasive and metastatic behavior.

TRIB1 Supports Prostate Tumorigenesis and Tumor-Propagating Cell Survival by Regulation of Endoplasmic Reticulum Chaperone Expression

Tetsuo Mashima, Taeko Soma-Nagae, Toshiro Migita, Ryoko Kinoshita, Atsushi Iwamoto, Takeshi Yuasa, Junji Yonese, Yuichi Ishikawa, and Hiroyuki Seimiya

Précis: Prostate cancer stem-like cells appear to be addicted to oncogenic signals from an endoplasmic reticulum-dependent stress response pathway, a finding with potential therapeutic implications.

IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma

Morteza Esmaeili, Bob C. Hamans, Anna C. Navis, Remco van Horssen, Tone F. Bathe, Ingrid S. Gribbestad, William P. Leenders, and Arend Heerschap

Précis: This study reports novel noninvasive biomarkers of IDH-mutant gliomas that may help to guide treatments to target aberrant metabolism in these aggressive brain tumors.

IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers

Pierfrancesco Marra, Sumi Mathew, Anita Grigoriadis, Yin Wu, Fernanda Kyle-Cezar, Johnathan Watkins, Mamunur Rashid, Emanuele De Rinaldis, Sonya Hessey, Patrycja Gazinska, Adrian Hayday, and Andrew Tutt

Précis: Expression of an immune memory-inducing receptor in some triple-negative breast cancers, usually only expressed by T cells, may offer a mechanistic explanation for the paradoxical association of some of these high-grade tumors with better survival outcomes.

Epigenetic Targeting of Ovarian Cancer Stem Cells

Yinu Wang, Horacio Cardenas, Fang Fang, Salvatore Condello, Pietro Taverna, Matthew Segar, Yunlong Liu, Kenneth P. Nephew, and Daniela Matei

Précis: These results suggest that epigenome-targeting strategies can reprogram residual cancer stem-like cells to a differentiated state, thereby helping prevent the development of recurrent, chemoresistant disease.

Live-Cell Imaging of Invasion and Intravasation in an Artificial Microvessel Platform

Andrew D. Wong and Peter C. Searson

Précis: An artificial microvessel platform can be used to obtain striking images and mechanistic insights into how cancer cells invade the local microenvironment and enter and exit vessels, providing a new tool to help unravel the complexities of metastasis and its prevention and treatment.

LETTERS TO THE EDITOR

A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1—Letter

Kenneth W. Thompson, Stefanie B. Marquez, and David Reisman

Proposal for a Synthetic Lethality Therapy Using the Paralog Dependence of Cancer Cells—Response

Takahiro Oike, Hideaki Ogihara, Takashi Nakano, and Takashi Kohno
CORRECTIONS

4950  Correction: The TGFβ–miR200–Mig6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors

4951  Correction: Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage-Sensing Checkpoint in Cancer

ABOUT THE COVER

Confocal microscopy analysis for osteopontin performed on myeloid-derived suppressor cells (MDSC) shows osteopontin (red) localized under the cellular membrane but not colocalized with the ER marker concanavalin A (green) in MDSC. This picture is suggestive of the existence of an intracellular form, rather than a secreted form of osteopontin, in MDSC. For details, see article by S. Sangaletti and colleagues on page 4706.
Cancer Research

74 (17)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/74/17

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.